Hercules Capital Inc - HTGC STOCK NEWS

Hercules Capital (NYSE: HTGC) has announced a supplemental cash distribution of $0.07 per share, to be paid on November 17, 2021. This is in addition to the regular quarterly distribution of $0.33 per share for Q3 2021. The supplemental payment will come from undistributed taxable income as of September 30, 2021. The company maintains a distribution policy aiming to distribute approximately 90%-100% of its taxable income, with 88.6% of the current distributions categorized as Qualified Interest Income exempt from U.S. withholding tax for non-U.S. shareholders.

Hercules Capital (NYSE: HTGC) has declared a cash distribution of $0.33 per share for Q3 2021. The record date is set for November 10, 2021, with payment occurring on November 17, 2021. The company maintains a variable distribution policy to distribute approximately 90% to 100% of its taxable income. For Q3 2021, 88.6% of the declared distributions were classified as Qualified Interest Income (QII), which may be exempt from U.S. withholding tax for non-U.S. shareholders. Hercules has committed over $12.0 billion to more than 530 companies since its inception.

Hercules Capital has appointed Pam Randhawa to its Board of Directors, effective November 1, 2021. With over 20 years in the healthcare and life sciences sectors, her background includes leadership positions at McKesson and her own firm, Empiriko Corporation. Randhawa's expertise is expected to enhance the board's capabilities as Hercules focuses on long-term growth and shareholder returns. CEO Scott Bluestein praised her contributions within the life sciences community, indicating her appointment is part of a strategy to bolster the company's leadership team.

Hercules Capital, Inc. (NYSE: HTGC) will release its third quarter 2021 financial results on October 28, 2021, after market close, followed by a conference call at 2:00 p.m. PT (5:00 p.m. ET). The call will be accessible via telephone and a live webcast on the company's investor relations website. Hercules Capital, a leading specialty finance provider, has committed over $12 billion to more than 530 companies since its inception in December 2003. The company primarily focuses on senior secured loans to high-growth, innovative firms.

Corium, Inc. has secured a $235 million term loan from Hercules Capital, Inc. to accelerate the commercialization of its ADHD treatment, AZSTARYS, and advance its pipeline. The loan includes an initial tranche of $100 million, with additional funds contingent on achieving specific milestones. AZSTARYS, approved by the FDA in March 2021, is the first product containing serdexmethylphenidate, aimed at treating ADHD in patients aged 6 and older. This financing reflects Hercules' confidence in Corium's growth potential.

Hercules Capital, Inc. (NYSE: HTGC) has announced a record achievement in its financing activities, originating over $1.5 billion in gross debt and equity commitments year-to-date, surpassing its previous record of $1.47 billion. This milestone reflects the firm's strong market presence and disciplined underwriting approach. The company has also recently completed a public offering of $325 million in 2.625% Notes, enhancing its liquidity and reducing overall debt costs, positioning itself for future investment opportunities.

Hercules Capital, Inc. (NYSE: HTGC) has completed a public offering of $325 million in 2.625% unsecured notes due September 16, 2026. The proceeds will be used to repurchase existing asset-backed notes, fund investments in debt and equity securities, and for general corporate purposes. The Notes, rated Baa3 and BBB+ by Moody's and Kroll Bond Rating Agency respectively, offer semiannual interest payments. Hercules continues to lead in providing growth loans to high-growth, venture-backed companies, having committed over $12 billion since its inception in December 2003.

Hercules Capital, Inc. (NYSE: HTGC) has priced a public offering of $325 million in 2.625% notes due September 2026. The unsecured notes will deliver interest semiannually and can be redeemed at the Company’s option. The net proceeds will be used to repurchase asset-backed notes, fund investments in debt and equity securities, and for general corporate purposes. The offering's completion is subject to customary closing conditions.

Better Therapeutics has secured a loan facility of up to $50 million from Hercules Capital (NYSE: HTGC) as part of a total financing package of $150 million, including a pending SPAC merger and PIPE investment. This funding aims to advance its clinical pipeline and commercialize its first prescription digital therapeutic (PDT) for type 2 diabetes. The company is at a pivotal point in its development, with ongoing studies to test their innovative cognitive behavioral therapy aimed at treating cardiometabolic diseases.